Danieli Maria Giovanna, Calcabrini Lucia, Marchetti Annalisa, Calabrese Vincenzina, Pettinari Lucia, Massaccesi Chiara, Gabrielli Armando, Danieli Giovanni
Clinica Medica, Dipartimento di Scienze Mediche e Chirurgiche, Università Politecnica delle Marche, Ancona.
Recenti Prog Med. 2007 Jun;98(6):322-6.
Our experience with intravenous immunoglobulin (IVIg) in autoimmune diseases is reported. In 16 subjects with polymyositis and dermatomyositis, IVIg has been given in case of steroid resistance or dependency. Subjects treated with IVIg achieved a clinical and functional remission in a higher percentage (81%), that was maintained after a mean five year follow-up period (p < 0.001), as compared to control group. In twelve subjects with new-onset Churg-Strauss disease, IVIg was added to standard treatment. In these patients, IVIg permitted to achieve a long-term stable remission with a good functional recovery with lower incidence of the steroid-associated side effects. In conclusion, IVIg can be safely employed in subjects with immune-mediated diseases, even in those with severe and refractory disease.
我们报告了静脉注射免疫球蛋白（IVIg）治疗自身免疫性疾病的经验。在16例多发性肌炎和皮肌炎患者中，对于类固醇抵抗或依赖的患者给予IVIg治疗。与对照组相比，接受IVIg治疗的患者临床和功能缓解率更高（81%），在平均五年的随访期后仍保持缓解（p<0.001）。在12例新发Churg-Strauss病患者中，IVIg被添加到标准治疗中。在这些患者中，IVIg使患者能够实现长期稳定缓解，功能恢复良好，且类固醇相关副作用的发生率较低。总之，IVIg可安全用于免疫介导疾病的患者，即使是那些患有严重难治性疾病的患者。
